

Lynn G Feun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5893986/publications.pdf>

Version: 2024-02-01

40
papers

2,210
citations

304743

22
h-index

315739

38
g-index

40
all docs

40
docs citations

40
times ranked

3041
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell analysis reveals new evolutionary complexity in uveal melanoma. <i>Nature Communications</i> , 2020, 11, 496.	12.8	268
2	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7660-7668.	1.6	218
3	Arginine Deprivation as a Targeted Therapy for Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 1049-1057.	1.9	197
4	Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. <i>Cancer Research</i> , 2012, 72, 2622-2633.	0.9	175
5	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3603-3614.	4.1	121
6	Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. <i>Journal of Clinical Oncology</i> , 2015, 33, 4093-4098.	1.6	120
7	Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 α /Sp4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3223-3233.	4.1	113
8	Pegylated arginine deiminase: a novel anticancer enzyme agent. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 815-822.	4.1	103
9	Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. <i>British Journal of Cancer</i> , 2012, 106, 1481-1485.	6.4	98
10	Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. <i>Oncotarget</i> , 2010, 1, 246-251.	1.8	81
11	Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. <i>Oncotarget</i> , 2017, 8, 49275-49292.	1.8	74
12	TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. <i>Molecular and Cellular Biochemistry</i> , 2013, 374, 181-190.	3.1	66
13	Arginine deprivation in cancer therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 78-82.	2.5	65
14	Optical coherence tomography imaging of melanoma skin cancer. <i>Lasers in Medical Science</i> , 2019, 34, 411-420.	2.1	64
15	Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. <i>Oncotarget</i> , 2015, 6, 6295-6309.	1.8	36
16	Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 105-117.	3.4	33
17	Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1 α , and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. <i>Oncotarget</i> , 2016, 7, 82658-82670.	1.8	33
18	Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. <i>Cancer Letters</i> , 2017, 388, 54-63.	7.2	32

#	ARTICLE	IF	CITATIONS
19	Targeting the Prolineâ€“Glutamineâ€“Asparagineâ€“Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy. Pharmaceuticals, 2021, 14, 72.	3.8	28
20	Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S13107.	1.3	27
21	Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 1297.	4.1	27
22	The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma. Drug Target Insights, 2007, 2, 117739280700200.	1.4	26
23	Arginine deprivation therapy for malignant melanoma. Clinical Pharmacology: Advances and Applications, 2013, 5, 11.	1.2	23
24	The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights, 2007, 2, 119-28.	1.4	21
25	Degradation of AMPKâ€“1 sensitizes BRAF inhibitorâ€“resistant melanoma cells to arginine deprivation. Molecular Oncology, 2017, 11, 1806-1825.	4.6	19
26	Topoisomerase I inhibitors for the treatment of brain tumors. Expert Review of Anticancer Therapy, 2008, 8, 707-716.	2.4	18
27	A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma. American Journal of Case Reports, 2014, 15, 441-443.	0.8	16
28	Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. Journal of Neuro-Oncology, 2007, 82, 177-181.	2.9	15
29	Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Translational Oncology, 2020, 13, 355-364.	3.7	15
30	Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. Journal of Cancer Research and Clinical Oncology, 2003, 129, 17-20.	2.5	14
31	Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. International Journal of Molecular Sciences, 2021, 22, 7379.	4.1	14
32	BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget, 2016, 7, 17665-17680.	1.8	13
33	Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 9-15.	3.7	12
34	Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. Anticancer Research, 2014, 34, 6991-9.	1.1	12
35	Cyclosporine A, alpha-Interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer Investigation, 2005, 23, 3-8.	1.3	4
36	Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. International Journal of Molecular Sciences, 2021, 22, 7628.	4.1	3

#	ARTICLE	IF	CITATIONS
37	Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 3555-63.	1.1	3
38	An Openâ€Label, Randomized, Multiâ€Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukinâ€2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. Oncolmunology, 2021, 10, 1984059.	4.6	2
39	Targeting Argininosuccinate Synthetase in Cancer Therapy. , 2012, , 37-51.		1
40	Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor. Scientific World Journal, The, 2002, 2, 125-126.	2.1	0